Bad (Ab-136) Antibody

What is BAD (Ab-136) Antibody and what cellular processes does it target?

BAD (Ab-136) Antibody is a polyclonal antibody raised in rabbits that targets the BCL-2-associated agonist of cell death (BAD) protein. The BAD protein is a member of the BCL-2 family, which functions as a regulator of programmed cell death. It positively regulates cell apoptosis by forming heterodimers with BCL-xL and BCL-2, thereby reversing their death repressor activity. The proapoptotic activity of BAD is regulated through phosphorylation by protein kinases AKT and MAP kinase, as well as protein phosphatase calcineurin . This antibody specifically recognizes the peptide sequence around amino acids 134-138 (S-R-S-A-P) derived from Mouse BAD .

What are the validated applications for BAD (Ab-136) Antibody?

BAD (Ab-136) Antibody has been validated for several laboratory applications including Western Blotting (WB), Immunohistochemistry (IHC), and Enzyme-Linked Immunosorbent Assay (ELISA) . For Western Blotting, the recommended dilution range is 1:500-1:1000, while for Immunohistochemistry, the optimal dilution range is 1:50-1:200 . The antibody detects endogenous levels of total BAD protein, making it suitable for studying native BAD expression and regulation in various experimental contexts .

What species reactivity has been confirmed for this antibody?

The BAD (Ab-136) Antibody has been validated to react with human, mouse, and rat samples . This cross-species reactivity makes it versatile for comparative studies across different mammalian model systems. When designing experiments involving other species, preliminary validation is recommended as reactivity may vary depending on the conservation of the epitope sequence across different organisms.

How should sample preparation be optimized for detecting BAD protein using the Ab-136 antibody?

For optimal detection of BAD protein using the Ab-136 antibody, sample preparation should include careful cell lysis techniques that preserve phosphorylation states. Since BAD activity is regulated by phosphorylation, phosphatase inhibitors should be included in lysis buffers. For Western blotting applications, protein samples should be denatured at 95°C for 5 minutes in sample buffer containing SDS and a reducing agent. For immunohistochemistry, tissue fixation with 4% paraformaldehyde is recommended, followed by appropriate antigen retrieval methods (typically heat-induced epitope retrieval in citrate buffer pH 6.0). Diluting the antibody in a buffer containing 1-5% normal serum from the same species as the secondary antibody helps reduce background signal .

What controls should be included when using BAD (Ab-136) Antibody in experimental procedures?

When using BAD (Ab-136) Antibody, several controls should be incorporated to ensure experimental rigor. For Western blotting, include a positive control (lysate from cells known to express BAD), a negative control (lysate from BAD-knockout cells), and a loading control (antibody against housekeeping proteins like β-actin or GAPDH). For immunohistochemistry, include tissue sections processed without primary antibody, tissue known to be negative for BAD expression, and positive control tissues. When evaluating phosphorylation changes, appropriate treatment controls (e.g., phosphatase treatment or kinase inhibitors) should be included to validate signal specificity . Antibody specificity can be further validated using peptide competition assays with the immunizing peptide sequence (S-R-S-A-P) .

How should BAD (Ab-136) Antibody be incorporated into antibody array experiments?

For incorporation into antibody arrays, BAD (Ab-136) Antibody should first be immobilized on a suitable surface using covalent attachment chemistry. Following the protocols similar to those described by Full Moon BioSystems, the antibody can be attached to glass surfaces coated with polymeric 3-D materials containing epoxy, aldehyde, and hydroxyl functional groups . For reliable results, include six replicates per antibody spot along with appropriate positive and negative controls. Sample proteins should be biotinylated using a protein labeling kit (such as FluoReporter Mini-Biotin-XX-Protein Labeling Kit) before incubation with the antibody array. After washing steps, detection can be achieved using fluorescently labeled streptavidin (e.g., Cy3-streptavidin). Quantification should involve subtracting background fluorescence values from each antibody spot signal .

What is the recommended protocol for using BAD (Ab-136) Antibody in Western Blotting?

For Western Blotting using BAD (Ab-136) Antibody:

• Prepare protein lysates from cells or tissues in an appropriate lysis buffer containing protease and phosphatase inhibitors.

• Quantify protein concentration using a reliable method (Bradford or BCA assay).

• Load 20-50 μg of protein per lane on an SDS-PAGE gel (10-12% acrylamide).

• Separate proteins by electrophoresis and transfer to a PVDF or nitrocellulose membrane.

• Block the membrane with 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature.

• Incubate with BAD (Ab-136) Antibody at a 1:500-1:1000 dilution in blocking buffer overnight at 4°C.

• Wash the membrane 3-4 times with TBST.

• Incubate with HRP-conjugated secondary antibody (anti-rabbit IgG) at 1:5000 dilution for 1 hour at room temperature.

• Wash again 3-4 times with TBST.

• Develop using enhanced chemiluminescence (ECL) substrate and image using an appropriate detection system.

The BAD protein should appear at approximately 23 kDa, though phosphorylated forms may show slight mobility shifts .

What protocol modifications are needed for Immunohistochemistry with BAD (Ab-136) Antibody?

For Immunohistochemistry using BAD (Ab-136) Antibody:

• Fix tissue sections in 4% paraformaldehyde and embed in paraffin.

• Section tissues at 4-6 μm thickness and mount on positively charged slides.

• Deparaffinize sections in xylene and rehydrate through graded alcohols to water.

• Perform antigen retrieval using citrate buffer (pH 6.0) at 95-100°C for 20 minutes.

• Allow slides to cool to room temperature and wash in PBS.

• Block endogenous peroxidase activity with 3% hydrogen peroxide for 10 minutes.

• Block non-specific binding with 5% normal goat serum in PBS for 1 hour.

• Incubate with BAD (Ab-136) Antibody at a 1:50-1:200 dilution in blocking buffer overnight at 4°C.

• Wash 3 times with PBS.

• Apply appropriate biotinylated secondary antibody for 30 minutes at room temperature.

• Wash 3 times with PBS.

• Apply streptavidin-HRP complex for 30 minutes.

• Develop with DAB substrate until optimal staining is achieved.

• Counterstain with hematoxylin, dehydrate, clear, and mount.

Positive staining for BAD should appear as brown coloration primarily in the cytoplasm of cells expressing the protein .

How can BAD (Ab-136) Antibody be adapted for use in multiplexed bead array assays?

To adapt BAD (Ab-136) Antibody for multiplexed bead array assays:

• Couple the antibody to carboxylated beads (e.g., -COOH Microspheres) following the manufacturer's protocol with EDC/NHS chemistry for covalent attachment.

• Store antibody-coupled beads in blocking buffer (PBS, pH 7.4, containing 0.1% BSA, 0.02% Tween-20, 0.05% NaN₃) at 4°C protected from light.

• Prior to use, sonicate the bead suspension for 2 minutes to disperse any aggregates.

• For each assay, use 1000-1500 beads per reaction in 20 μL volume.

• Incubate beads with biotinylated cell lysate (prepared as described for antibody arrays) for 30 minutes in a 96-well plate format.

• Add phycoerythrin-labeled streptavidin (PE-SA, approximately 1.5 μg in 10 μL) as the fluorescent reporter.

• Incubate for 10 minutes before fluorescence readout.

• Up to seven different bead populations, each coated with different antibodies (including BAD Ab-136), can be combined for multiplexed detection.

• Optimize protein concentration in the range of 250 μg/L to 50 mg/L.

This approach allows simultaneous detection of BAD along with other proteins involved in related signaling pathways, providing a comprehensive view of pathway activation states .

What are common causes of weak or absent signal when using BAD (Ab-136) Antibody?

Several factors can contribute to weak or absent signal when using BAD (Ab-136) Antibody:

• Insufficient protein concentration - BAD is often expressed at relatively low levels, so ensure adequate protein loading (40-60 μg for Western blot).

• Degraded antibody - The antibody should be stored at -20°C for long-term storage; repeated freeze-thaw cycles can degrade antibody performance .

• Inadequate antigen retrieval - For IHC applications, optimize antigen retrieval methods (try extending citrate buffer heating time).

• Inappropriate blocking - Test alternative blocking agents (BSA vs. milk) as the epitope recognition may be sensitive to blocking conditions.

• Suboptimal antibody dilution - Titrate the antibody concentration to determine optimal working dilution.

• Cell/tissue preparation issues - Ensure samples are prepared to preserve protein phosphorylation state by including phosphatase inhibitors.

• Insufficient incubation time - For low abundance proteins, extending primary antibody incubation to 24-48 hours at 4°C may improve signal.

Testing positive control samples known to express BAD protein can help determine whether the issue is with the antibody or the experimental samples .

How can background signal be reduced when using BAD (Ab-136) Antibody in immunohistochemistry?

To reduce background signal in immunohistochemistry with BAD (Ab-136) Antibody:

• Optimize blocking conditions by testing different concentrations (3-10%) of normal serum from the same species as the secondary antibody.

• Include 0.1-0.3% Triton X-100 in blocking and antibody diluent solutions to reduce non-specific binding.

• Perform additional blocking steps with avidin-biotin blocking kit if using biotinylated secondary antibodies.

• Increase washing duration and frequency (5 washes of 5 minutes each) with PBS containing 0.05-0.1% Tween-20.

• Dilute the primary antibody in blocking solution containing 1% BSA to improve signal-to-noise ratio.

• Pre-absorb the primary antibody with tissue powder from the same species to remove cross-reactive antibodies.

• Reduce the concentration of secondary antibody if background persists.

• Use IHC-specific diluents that contain background-reducing components.

• If tissue contains endogenous biotin, use non-biotin detection systems or additional biotin blocking steps.

Implementing these strategies should help distinguish specific BAD protein staining from non-specific background .

How can BAD (Ab-136) Antibody be utilized to study apoptotic pathways in cancer research?

BAD (Ab-136) Antibody can be strategically employed in cancer research to investigate apoptotic dysregulation:

• Comparative expression analysis: Examine BAD protein levels across normal tissues, primary tumors, and metastatic samples using IHC and Western blotting to establish correlation with disease progression.

• Phosphorylation state analysis: Since BAD activity is regulated by phosphorylation, use phospho-specific antibodies alongside BAD (Ab-136) to assess the ratio of phosphorylated (inactive) to total BAD protein across tumor samples.

• Drug response studies: Monitor changes in BAD expression and phosphorylation status following treatment with chemotherapeutics or targeted therapies to assess apoptotic pathway activation.

• Co-immunoprecipitation experiments: Use BAD (Ab-136) Antibody to pull down BAD protein complexes and identify binding partners (BCL-2, BCL-xL) in different cancer contexts.

• Subcellular localization: Perform immunofluorescence studies to track BAD translocation between cytosol and mitochondria during apoptotic signaling.

• Combination with flow cytometry: Correlate BAD expression with apoptotic markers through multiparameter flow cytometry in cancer cell populations.

This multifaceted approach provides insights into how BAD-mediated apoptotic mechanisms are altered in cancer and how they might be targeted therapeutically .

What approaches can be used to validate BAD (Ab-136) Antibody specificity for critical research applications?

For critical research applications requiring high confidence in antibody specificity, several validation approaches should be implemented:

• Peptide competition assay: Pre-incubate BAD (Ab-136) Antibody with excess immunizing peptide (S-R-S-A-P) before application to samples. Specific signals should be eliminated or significantly reduced.

• Genetic validation: Test the antibody on samples from BAD knockout models or cells with CRISPR-Cas9 mediated BAD depletion. No signal should be detected in these samples.

• Orthogonal detection methods: Confirm BAD expression using independent detection methods such as RNA-seq or qPCR to correlate protein detection with transcript levels.

• Multiple antibody validation: Compare results with other BAD antibodies targeting different epitopes.

• Mass spectrometry validation: Perform immunoprecipitation with BAD (Ab-136) Antibody followed by mass spectrometry to confirm the identity of the precipitated protein.

• Public antibody validation repositories: Cross-reference with data from antibody validation initiatives like Antibodypedia or the Human Protein Atlas.

• Independent laboratory reproduction: Have results verified by an independent laboratory using the same antibody lot.

How can BAD (Ab-136) Antibody be incorporated into high-throughput screening assays for apoptosis modulators?

BAD (Ab-136) Antibody can be effectively incorporated into high-throughput screening platforms:

• Cell-based ELISA format: Grow cells in 96- or 384-well plates, treat with compound libraries, fix, and detect BAD expression/phosphorylation using BAD (Ab-136) Antibody with HRP-conjugated secondary antibody and colorimetric readout.

• Automated microscopy platforms: Develop an immunofluorescence protocol using BAD (Ab-136) Antibody for high-content screening systems to assess BAD expression, localization, and co-localization with other apoptotic proteins.

• Bead-based multiplex assays: Couple BAD (Ab-136) Antibody to distinct color-coded beads for flow cytometry-based multiplexed detection alongside other apoptotic markers.

• Antibody microarrays: Immobilize BAD (Ab-136) Antibody in microarray format to screen multiple samples simultaneously for BAD expression or binding partners.

• ALPHA screen technology: Adapt BAD (Ab-136) Antibody for Amplified Luminescent Proximity Homogeneous Assay to detect protein-protein interactions involving BAD.

• Time-resolved FRET assays: Develop TR-FRET assays using labeled BAD (Ab-136) Antibody to detect conformational changes or interaction dynamics in real-time.

These approaches enable efficient screening of thousands of compounds for their effects on BAD-mediated apoptotic pathways, facilitating drug discovery efforts for cancer and other diseases involving dysregulated apoptosis .

How can BAD (Ab-136) Antibody data be integrated with transcriptomic analyses for comprehensive pathway investigation?

Integrating BAD (Ab-136) Antibody data with transcriptomics provides a multi-level understanding of apoptotic regulation:

• Correlation analysis: Compare BAD protein levels detected by the antibody with BAD mRNA expression from RNA-seq or microarray data to identify post-transcriptional regulation mechanisms.

• Pathway enrichment: Combine proteomics data from BAD immunoprecipitation with transcriptomics to identify enriched functional pathways and regulatory networks.

• Transcription factor analysis: Correlate changes in BAD protein levels with transcription factor activity to identify upstream regulators.

• Alternative splicing investigation: Use BAD (Ab-136) Antibody Western blots alongside RNA-seq to detect whether specific BAD isoforms are preferentially expressed in different conditions.

• Time-course experiments: Perform temporal analyses comparing the kinetics of mRNA and protein changes after experimental perturbations.

• Single-cell correlation: In advanced applications, correlate BAD protein levels in single cells (using immunofluorescence) with single-cell RNA-seq data to understand cell-to-cell variability.

This integrated approach provides insights into the relationship between transcriptional control and protein-level regulation of BAD in different biological contexts .

What statistical approaches are recommended for analyzing antibody array data including BAD (Ab-136) Antibody?

For robust analysis of antibody array data involving BAD (Ab-136) Antibody:

• Normalization methods: Apply robust normalization techniques such as quantile normalization or VSN (variance stabilizing normalization) to account for technical variability across arrays.

• Background correction: Subtract local background from each antibody spot, as described in antibody array protocols: "final fluorescence signal (I) was obtained from the fluorescence intensity of each antibody spot after subtraction of the blank signal" .

• Replicate analysis: For the six replicates typically used in antibody arrays, calculate mean values and standard deviations to assess technical reproducibility.

• Differential expression analysis: Use appropriate statistical tests (t-tests for pairwise comparisons or ANOVA for multiple groups) with multiple testing correction (FDR or Bonferroni).

• Correlation analysis: Perform correlation analysis between BAD and other proteins on the array to identify co-regulated proteins.

• Hierarchical clustering: Apply unsupervised clustering to identify patterns of protein expression across experimental conditions.

• Principal Component Analysis: Use PCA to reduce dimensionality and visualize relationships between samples.

• Network analysis: Construct protein interaction networks based on correlation patterns to place BAD in its functional context.